Background
Elezanumab is a fully humanized monoclonal antibody directed against repulsive guidance molecule A (RGMa). Studies in patients with multiple sclerosis (MS) demonstrate RGMa upregulation, which inhibits axonal growth and myelination, oligodendroglial regeneration and functional recovery after trauma or inflammation. Elezanumab treatment promoted axon regeneration, neuroprotection, remyelination, and immune modulation in several MS-relevant preclinical models. Elezanumab was previously well-tolerated as a single dose to healthy volunteers.• Molecular biology, genetics and biochemistry of the repulsive guidance molecule family., PMID:19698085• Expression pattern of the repulsive guidance molecules RGM A, B and C during mouse development., PMID:15053976• DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive properties., PMID:14985445• TACE cleaves neogenin to desensitize cortical neurons to the repulsive guidance molecule., PMID:21645559• Repulsive guidance molecules lock growth differentiation factor 5 in an inhibitory complex., PMID:32576689